Storia in 2 fonti

Chai Discovery unveils Chai-3, advancing AI drug design capabilities

Chai Discovery's Chai-3 model doubles antibody design success rates, lands a Pfizer licensing deal, and raises $400M at a $3.8B valuation in

Raccontata da

latent.space

cryptobriefing.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

cryptobriefing.comStai leggendo12 h fa

Chai Discovery unveils Chai-3, advancing AI drug design capabilities

Chai-3 reaches 50% therapeutic binding success (vs single-digit baseline), landing Pfizer's deal and $400M Series C. The tenfold AI efficiency gain forces pharma to adopt generative molecular design: drug discovery compresses from years to weeks.

originale

latent.space13 h fa

🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery

Chai Discovery closed 4 pharma deals with production-ready binding AI for drug design: Lilly, Novartis, argenx. Binding AI transforms discovery from multi-year iteration into engineering, shortening clinic paths and shifting R&D spend to outsourced AI.

Leggi questa versione →

Timeline cronologica

martedì 11 agosto 2026·latent.space
🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery
Pharma is suddenly paying for Bio × AI tools, and Chai is leading the pack with four deals closed this summer. Cofounder Matt McPartlon and Product leader Neil Patil explain why.
mercoledì 12 agosto 2026·cryptobriefing.com
Chai Discovery unveils Chai-3, advancing AI drug design capabilities
Chai Discovery's Chai-3 model doubles antibody design success rates, lands a Pfizer licensing deal, and raises $400M at a $3.8B valuation in